Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Airline Industry Today.
Press releases published on April 25, 2025
XRP News: XenDex Surpasses 10% Presale Allocation Within Hours of Launch
GlobeNewswire
·
April 25, 2025
SYDNEY, April 25, 2025 (GLOBE NEWSWIRE) -- XenDex the first cross-chain decentralized exchange on the XRP Ledger, offering AI-assisted copy trading, non-custodial lending and borrowing, and seamless interoperability across blockchain networks is currently …
Priority Income Fund Announces Intent to Seek Public Listing of Shares of Common Stock
GlobeNewswire
·
April 25, 2025
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Priority Income Fund, Inc. (“Priority Income Fund” or the “Fund”) is pleased to announce today that the Fund intends to seek to list shares of its common stock on a national securities exchange, with a target …
PER® Presents More Than a Dozen Free CME/CE Symposia at the Annual Oncology Meeting in Chicago
GlobeNewswire
·
April 25, 2025
CHICAGO, April 25, 2025 (GLOBE NEWSWIRE) -- This May, during one of the most important weeks in cancer care, Physicians’ Education Resource®, LLC (PER®), the go-to educational resource for health care professionals across all specialties to advance patient …
Advanced BioNutritionals Under Review: Highly-Trusted Supplement Brand for Quality Products
GlobeNewswire
·
April 25, 2025
New York City, April 25, 2025 (GLOBE NEWSWIRE) -- In This Article, You’ll Discover: The most common supplement-related health concerns people face today Why supplement quality, formulation, and transparency matter more than ever How Advanced …
SightFresh Under Review: Secret Vision Berry to Restore Eyesight with Sight Fresh Ingredients
GlobeNewswire
·
April 25, 2025
New York City, April 25, 2025 (GLOBE NEWSWIRE) -- In This Article, You'll Discover: The hidden causes behind the sharp rise in vision problems in 2025 How digital screens, pollution, and aging contribute to visual decline What the SightFresh supplement is, …
Top Technology Executives Recognized at the 2025 HoustonCIO ORBIE Awards
GlobeNewswire
·
April 25, 2025
Leading CIOs honored for leadership, innovation, and business impact. HOUSTON, April 25, 2025 (GLOBE NEWSWIRE) -- The 2025 HoustonCIO ORBIE Awards recognized the exceptional leadership and innovation of top technology executives from Chevron, NOV, Nabors, …
HPQ Silicium : Correction de communiqués antérieurs
GlobeNewswire
·
April 25, 2025
En réponse à une demande formulée par l’Autorité des marchés financiers, HPQ Silicium procède à la publication d’un communiqué rectificatif visant à corriger certaines informations à caractère prospectif diffusées dans des communiqués antérieurs. MONTRÉAL, …
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
GlobeNewswire
·
April 25, 2025
Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders Mouse analog of MICVO in a syngeneic model …
Starton Therapeutics Presents Positive Data from Phase 1b Study Evaluating STAR-LLD for the Treatment of Relapsed/Refractory Multiple Myeloma at the American Association for Cancer Research (AACR) Annual Meeting 2025
GlobeNewswire
·
April 25, 2025
PARAMUS, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced today the presentation of positive data …
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
GlobeNewswire
·
April 25, 2025
- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated promising anti-tumor activity - Combination …
T-knife Therapeutics Presents Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting Demonstrating a Potential Best-in-Class PRAME Targeted TCR-T Therapy
GlobeNewswire
·
April 25, 2025
– TK-6302, a supercharged PRAME targeting TCR-T therapy, demonstrates best-in-class preclinical anti-tumor efficacy as compared to current clinical stage PRAME TCR-T approaches, providing the potential for broad, deep and durable responses in hard-to-treat …
Harbinger Health Unveils Promising New Data on Early Cancer Detection Platform at AACR 2025
GlobeNewswire
·
April 25, 2025
Novel analytical framework establishes a clinically meaningful performance assessment of blood-based early detection tests Innovative methodology enhances cancer signal detection, boosts specificity and predictive value Presentations further validate the …
DTE Completes Construction on Pine River Solar Park
GlobeNewswire
·
April 25, 2025
Detroit, April 25, 2025 (GLOBE NEWSWIRE) -- DTE Energy (NYSE:DTE), Michigan’s largest producer of and investor in renewable energy, announced that construction has been completed at Pine River Solar Park during a ribbon-cutting ceremony at the site today. …
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
GlobeNewswire
·
April 25, 2025
Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission expected in 1H-2026 VANCOUVER, British Columbia, April …
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
GlobeNewswire
·
April 25, 2025
BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events BDC-3042 showed biological activity, with clear dose-dependent increases in proinflammatory cytokines and chemokines BDC-3042 showed …
Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025
GlobeNewswire
·
April 25, 2025
Activity in preclinical models of ovarian, prostate, and non-small cell lung cancer supports potential utility of OP-3136, a KAT6 inhibitor, in indications beyond breast cancer Patient recruitment ongoing in Phase 1 trial of OP-3136 as a monotherapy and in …
IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170
GlobeNewswire
·
April 25, 2025
Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage …
Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets
GlobeNewswire
·
April 25, 2025
Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour BRAF degrader demonstrates broad activity across all three BRAF mutation classes Aurora A kinase …
Enable Injections Presents Survey Results Highlighting Missed Opportunities in Subcutaneous Oncology Drug Development at AACR 2025
GlobeNewswire
·
April 25, 2025
CINCINNATI, April 25, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® wearable drug delivery platform, announced today the presentation of a poster featuring new findings …
Towards the Light: Co-creating a New Global Journey in the AI Field — The Grand 2025 AI Intelligent Development Summit
GlobeNewswire
·
April 25, 2025
Hong Kong, April 25, 2025 (GLOBE NEWSWIRE) -- On April 22, 2025, the "Towards the Light: Co-creating a New Global Journey in the AI Field — 2025 AI Intelligent Development Summit" grandly opened at the Hop Hing Hotel in Hong Kong, China. This forum focused …